However, heterogeneity test revealed no evidence of a difference in the observed effects for the three aggressive subtypes, ER+ high proliferation, HER2+ and TN tumours, after adjusting the confounding variables (p = 0.91 and 0.90 in BCSS and DMFS, respectively; data not shown). The gene discussed is ERBB2; the disease is neoplasm.